Franck Pourcine

Franck Pourcine

Auto-generated profile, based on publicly available information

Franck Pourcine

Groupe Hospitalier Sud Ile de France, Service de Réanimation, Melun, France

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2018 in American Journal of Kidney Diseases
Verified
Journal Article
Closed access
PDF file
MQMoglie Le Quintrec
Moglie Le Quintrec
ALAnne-Laure Lapeyraque
Anne-Laure Lapeyraque
ALArnaud Lionet
Arnaud Lionet
ASAnne-Laure Sellier-Leclerc
Anne-Laure Sellier-Leclerc
YDYahsou Delmas
Yahsou Delmas
FFFadi Fakhouri
Fadi Fakhouri

3 March 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
FPFranck Pourcine
Franck Pourcine
KDKarine Dahan
Karine Dahan
FMFabrice Mihout
Fabrice Mihout
MCMarine Cachanado
Marine Cachanado
IBIsabelle Brocheriou
Isabelle Brocheriou
Pierre RONCOPierre RONCO
Pierre RONCO
Clinical course of membranous nephropathy (MN) is difficult to predict. Measurement of circulating anti-PLA2R autoantibodies (PLA2R-Ab) and detection in immune deposits of PLA2R antigen (PLA2R-Ag) are major advances in disease understanding. We evaluated the clinical significance of these biomarkers. In this 14-year retrospective study, we collected data from 108 MN patients and assessed the relationship between clinical course, PLA2R-Ab and PLA2R-Ag. We also assessed THSD7A status. Eighty-five patients suffered from primary MN (PMN) and 23 patients from a secondary form. The median follow-up was 30.4 months [interquartile range, 17.7;56.7]. Among the 77 patients with PMN and available serum and/or biopsy, 69 (89.6%) had PLA2R-related disease as shown by anti-PLA2R-Ab and/or PLA2R-Ag, while 8 patients (8/77, 10.4%) were negative for both. There was no significant difference between these two groups in age at diagnosis and outcome assessed by proteinuria, serum albumin level and eGFR. Two of the 8 negative patients were positive for THSD7A. In patients with PLA2R related PMN, younger age, lower proteinuria, higher eGFR, and lower PLA2R-Ab level at baseline and after 6 months were associated with remission of proteinuria. Initial PLA2R-Ab titer ≤ 97.6 RU/mL and complete depletion of PLA2R-Ab within 6-months were significantly associated with spontaneous remission at the end of follow-up. In rituximab treated patients, lower PLA2R-Ab titer at initiation of treatment, and absence of PLA2R-Ab and higher serum albumin level at 3 months were significantly associated with remission. Noticeably, 81.8% of the patients who achieved remission completely cleared PLA2R-Ab. Depletion of PLA2R-Ab and increase of serum albumin level preceded the decrease of proteinuria. Assessment of PLA2R autoimmunity is essential for patient management. Combination of PLA2R-Ab and PLA2R-Ag increases diagnosis sensitivity. PLA2R-Ab titer is a biomarker of disease severity at initial assessment, and the kinetics of the antibody are significantly correlated to disease evolution.

24 May 2020 in Annals of Intensive Care
Verified
Journal Article
Open access
PDF file
SJSebastien Jochmans
Sebastien Jochmans
SMSandie Mazerand
Sandie Mazerand
JCJonathan Chelly
Jonathan Chelly
FPFranck Pourcine
Franck Pourcine
OSOumar Sy
Oumar Sy
MMMehran Monchi
Mehran Monchi
Prone position (PP) is highly recommended in moderate-to-severe ARDS. However, the optimal duration of PP sessions remains unclear. We searched to evaluate the time required to obtain the maximum physiological effect, and to search for parameters related to patient survival in PP. It was a prospective, monocentric, physiological study. We included in the study all prone-positioned patients in our ICU between June 2016 and January 2018. Pulmonary mechanics, data from volumetric capnography and arterial blood gas were recorded before prone positioning, 2 h after proning, before return to a supine position (SP) and 2 h after return to SP. Dynamic parameters were recorded before proning and every 30 min during the session until 24 h. 103 patients (ARDS 95%) were included performing 231 PP sessions with a mean length of 21.5 ± 5 h per session. They presented a significant increase in pH, static compliance and PaO2/FiO2 with a significant decrease in PaCO2, Pplat, phase 3 slope of the volumetric capnography, PetCO2, VD/VT-phy and ΔP. The beneficial physiological effects continued after 16 h of PP and at least up to 24 h in some patients. The evolution of the respiratory parameters during the first session and also during the pooled sessions did not find any predictor of response to PP, whether before, during or 2 h after the return in SP. PP sessions should be prolonged at least 24 h and be extended in the event that the PaO2/FiO2 ratio at 24 h remains below 150, especially since no criteria can predict which patient will benefit or not from it. Trial registration The trial has been registered on 28 June 2016 in ClinicalTrials.gov (NCT 02816190) (https://clinicaltrials.gov/ct2/show/NCT02816190?term=propocap&rank=1).

1 December 2018 in Kidney International
Verified
Journal Article
Closed access
PRPhilippe Rémy
Philippe Rémy
VAVincent Audard
Vincent Audard
PNPierre André Natella
Pierre André Natella
GPGaëlle Pelle
Gaëlle Pelle
BDBertrand Dussol
Bertrand Dussol
PVPhilippe Vanhille
Philippe Vanhille

23 June 2021 in Frontiers in Immunology
Verified
Journal Article
Open access
IBIdris Boudhabhay
Idris Boudhabhay
MRMarion Rabant
Marion Rabant
LRLubka T. Roumenina
Lubka T. Roumenina
LCLouis-Marie Coupry
Louis-Marie Coupry
VPVictoria Poillerat
Victoria Poillerat
FPFranck Pourcine
Franck Pourcine
Background: The coronavirus disease 2019 (COVID-19) pandemic has affected millions of people worldwide. A clinical series of Kawasaki-like multisystem inflammatory syndrome (MIS), occurring after SARS-CoV-2 infection, have been described in children (MIS-C) and adults (MIS-A), but the pathophysiology remains unknown. Case Presentation: We describe a case of post-COVID-19 MIS-A in a 46-year-old man with biopsy-proven renal thrombotic microangiopathy (TMA). Specific complement inhibition with eculizumab was initiated promptly and led to a dramatic improvement of renal function. Conclusion: Our case suggests that that TMA could play a central role in the pathophysiology of post-COVID-19 MIS-A, making complement blockers an interesting therapeutic option.

1 November 2020 in Resuscitation
Verified
Journal Article
Closed access
JCJonathan Chelly
Jonathan Chelly
AMAlain-Gil Mpela
Alain-Gil Mpela
SJSebastien Jochmans
Sebastien Jochmans
JBJennifer Brunet
Jennifer Brunet
SLStéphane Legriel
Stéphane Legriel
MMMerhan Monchi
Merhan Monchi